May 2nd 2024
The April 2024 cardiology month in review spotlights FDA news and top updates from the American College of Cardiology 2024 Scientific Session.
FDA Approves Subcutaneous Vedolizumab for Moderate to Severe UC
September 28th 2023Data from the VISIBLE 1 trial showed more patients receiving subcutaneous vedolizumab achieved clinical remission, mucosal healing, durable clinical response, durable clinical remission, and corticosteroid-free clinical remission compared to those receiving placebo.
FDA Approves Phentolamine Ophthalmic Solution for Pharmacologically-Induced Mydriasis
September 27th 2023According to the approval, the percentage of study eyes returning to ≤0.2 mm from baseline pupil diameter was statistically significantly greater in the phentolamine ophthalmic solution group than placebo.
CVS, Walgreens Among Companies to Receive FDA Warning for Marketing Unapproved Eye Drops
September 12th 2023On September 12, 2023, the FDA announced it had issued warning letters to 8 companies, including CVS Health and Walgreens, for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law.